NCT02097082View on ClinicalTrials.gov

Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 30, 2016

Study Completion Date

May 31, 2017

Conditions
Peripheral Arterial DiseaseIntermittent ClaudicationVascular DiseasesCardiovascular Diseases
Interventions
DEVICE

STANZA Drug-eluting resorbable Scaffold

Trial Locations (9)

1140

WGKK - Hanusch-Krankenhaus, Vienna

79189

Universitäts-Herzzentrum Freiburg-Bad Krozingen GmbH, Bad Krozingen

83022

RoMed Klinikum Rosenheim, Rosenheim

Unknown

Universitäts Klinikum Graz, Graz

Cardiovascular and Interventional Radiology- AKH, Vienna

Auckland City Hospital, Auckland

INSELSPITAL, Universitätsspital Bern, Bern

04103

Universitätsklinikum Leipzig AöR, Leipzig

CH-8091

University Hospital Zurich, Zurich

Sponsors

Lead Sponsor

480 Biomedical
All Listed Sponsors
lead

480 Biomedical

INDUSTRY

NCT02097082 - Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System | Biotech Hunter | Biotech Hunter